1. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia by Adele K. Fielding, Jacob M. Rowe, Georgina Buck, Letizia Foroni, Gareth Gerrard, Mark R. Litzow, Hillard Lazarus, Selina M. Luger, David I. Marks, Andrew K. McMillan, Anthony V. Moorman, Bella Patel, Elisabeth Paietta, Martin S. Tallman, and Anthony H. Goldstone Blood Volume 123(6):843-850 February 6, 2014 ©2014 by American Society of Hematology

2. A flowchart of all patients entered into the Ph+ arm of UKALLXII/E2993. Adele K. Fielding et al. Blood 2014;123:843-850 ©2014 by American Society of Hematology

3. Kaplan Meier plot of 10-year OS of all patients with Ph+ ALL by cohort. Adele K. Fielding et al. Blood 2014;123:843-850 ©2014 by American Society of Hematology

4. A flowchart of postremission treatment. Adele K. Fielding et al. Blood 2014;123:843-850 ©2014 by American Society of Hematology

5. Kaplan Meier plot of 4-year OS in the imatinib cohort. Adele K. Fielding et al. Blood 2014;123:843-850 ©2014 by American Society of Hematology

6. Kaplan Meier plot of 4-year OS in all patients with Ph+ ALL who did not receive alloHSCT, by preimatinib vs imatinib cohort. Adele K. Fielding et al. Blood 2014;123:843-850 ©2014 by American Society of Hematology